Business
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa., May 18, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.
About this update from Savara, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8f79247692080698bb4f0e666b500754"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PS5edxqRT7AXbmWdWuqgNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/8f79247692080698bb4f0e666b500754","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/tRupdFaRQtbxAehpFWoyxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/8f79247692080698bb4f0e666b500754","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ylVbNG_kdLACDdKRlsxzpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/8f79247692080698bb4f0e666b500754","width":1024,"height":512}},"lazy":false},{"type":"text","content":"-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"LANGHORNE, Pa., May 18, 2026--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP.","length":472,"tagName":"p"},{"type":"text","content":"Below is a summary of the data presented.","length":41,"tagName":"p"},{"type":"text","content":"Oral Presentation, Abstract 9296: "Molgramostim Improves Exercise Distance and Duration in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial," presented by B.C. Trapnell, M.D.; sponsored by Savara Inc.","length":274,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presented exercise capacity data from IMPALA-2, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial in which adults with aPAP received nebulized molgramostim 300 µg (n=81) or placebo (n=83) once daily for 48 weeks. IMPALA-...